Mepenzolate bromide in mucomembranous colitis. A report from the General Practitioner research group.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001561:Benzilates / Q000009:adverse effects / Q000627:therapeutic use; D001965:Bromides / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003061:Codeine / Q000009:adverse effects / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D003967:Diarrhea / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D001561:Benzilates; D001965:Bromides; D010276:Parasympatholytics; D010880:Piperidines; D000644:Quaternary Ammonium Compounds; D003061:Codeine